Skip Navigation


Nicotine & Tobacco Research Advance Access originally published online on February 26, 2009
Nicotine & Tobacco Research 2009 11(3):308-312; doi:10.1093/ntr/ntn032
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Article Summary
Right arrow All Versions of this Article:
11/3/308    most recent
ntn032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tidey, J. W.
Right arrow Articles by Rohsenow, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tidey, J. W.
Right arrow Articles by Rohsenow, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Intention to quit moderates the effect of bupropion on smoking urge

Jennifer W. Tidey and Damaris J. Rohsenow

Jennifer W. Tidey, Ph.D., Department of Psychiatry and Human Behavior, Brown University Center for Alcohol and Addiction Studies, and Providence VA Medical Center, Providence, RI
Damaris J. Rohsenow, Ph.D., Providence VA Medical Center and Brown University Center for Alcohol and Addiction Studies, Providence, RI

Corresponding Author: Jennifer W. Tidey, Ph.D., Brown University Center for Alcohol and Addiction Studies, Box S121-5, Providence, RI 02912, USA. Telephone: 401-863-6418. Fax: 401-863-6697. Email: jennifer_tidey{at}brown.edu


  Abstract

Introduction: The behavioral mechanisms by which bupropion reduces smoking have been explored in laboratory behavioral studies, with some inconsistent results. Intention to quit smoking has been found to moderate some effects of nicotine replacement, and the degree to which that characteristic may affect responses to other smoking pharmacotherapies is unknown.

Methods: This laboratory study examined the effects of 300 mg/day bupropion, compared with placebo, on baseline and smoking cue–elicited urge to smoke and other measures in smokers who stated that they did (n = 8) or did not (n = 17) intend to quit smoking within 6 months.

Results: Significant interactions indicated that bupropion reduced the effects of acute abstinence on smoking urges in the presence of neutral cues, only in those who intended to quit. Bupropion and intention to quit did not reduce the effects of acute abstinence on urges in the presence of smoking cues and did not reduce nicotine withdrawal symptoms or smoking behavior between sessions.

Discussion: This study is one of the first placebo-controlled examinations of the effects of bupropion on cue reactivity and provides support for the idea that laboratory smoking studies may be more likely to detect effects of pharmacological treatments for smoking when they enroll smokers who intend to quit.

Received: April 11, 2008; Accepted: July 10, 2008
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.